Status:
COMPLETED
First-in-Human Single and Multiple Dose of GLPG1205
Lead Sponsor:
Galapagos NV
Conditions:
Healthy
Eligibility:
MALE
18-50 years
Phase:
PHASE1
Brief Summary
The purpose of this First-in-Human study is to evaluate the safety and tolerability after single ascending oral doses of GLPG1205 given to healthy male subjects, compared to placebo. Also, the safety ...
Eligibility Criteria
Inclusion
- Healthy male, age 18-50 years
- BMI between 18-30 kg/m2
Exclusion
- Any condition that might interfere with the procedures or tests in this study
- Drug or alcohol abuse
- Smoking
Key Trial Info
Start Date :
June 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2013
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01887106
Start Date
June 1 2013
End Date
October 1 2013
Last Update
October 16 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
SGS LSS Clinical Pharmacology Unit Antwerp
Antwerp, Antwerp, Belgium